414 related articles for article (PubMed ID: 34791940)
41. Human cytomegalovirus and Epstein-Barr virus infections occurring early after transplantation are risk factors for antibody-mediated rejection in heart transplant recipients.
Saldan A; Mengoli C; Sgarabotto D; Fedrigo M; Angelini A; Feltrin G; Gambino A; Gerosa G; Barzon L; Abate D
Front Immunol; 2023; 14():1171197. PubMed ID: 37256129
[TBL] [Abstract][Full Text] [Related]
42. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers.
Maurmann S; Fricke L; Wagner HJ; Schlenke P; Hennig H; Steinhoff J; Jabs WJ
J Clin Microbiol; 2003 Dec; 41(12):5419-28. PubMed ID: 14662920
[TBL] [Abstract][Full Text] [Related]
43. [How to manage EBV reactivation and EBV-PTLD, CMV and human herpesvirus 6 reactivation and infection after allogeneic stem cell transplantation: A report of the SFGM-TC (update)].
Brissot E; Alsuliman T; Gruson B; Hermet E; Tirefort Y; Yakoub-Agha I; Alain S
Bull Cancer; 2017 Dec; 104(12S):S181-S187. PubMed ID: 29169653
[TBL] [Abstract][Full Text] [Related]
44. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients.
Hornef MW; Bein G; Fricke L; Steinhoff J; Wagner HJ; Hinderer W; Sonneborn HH; Kirchner H
Transplantation; 1995 Sep; 60(5):474-80. PubMed ID: 7676497
[TBL] [Abstract][Full Text] [Related]
45. BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study.
Blazquez-Navarro A; Dang-Heine C; Wittenbrink N; Bauer C; Wolk K; Sabat R; Westhoff TH; Sawitzki B; Reinke P; Thomusch O; Hugo C; Or-Guil M; Babel N
EBioMedicine; 2018 Aug; 34():113-121. PubMed ID: 30072213
[TBL] [Abstract][Full Text] [Related]
46. Cytomegalovirus reactivation in critically ill immunocompetent patients.
Limaye AP; Kirby KA; Rubenfeld GD; Leisenring WM; Bulger EM; Neff MJ; Gibran NS; Huang ML; Santo Hayes TK; Corey L; Boeckh M
JAMA; 2008 Jul; 300(4):413-22. PubMed ID: 18647984
[TBL] [Abstract][Full Text] [Related]
47. [Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus].
Song T; Chen G; Zhang X; Xu Y; Chen J; Wang Y; Ye L; Xu J; Wu D; Miao J
Zhonghua Yi Xue Za Zhi; 2014 Nov; 94(40):3135-9. PubMed ID: 25573307
[TBL] [Abstract][Full Text] [Related]
48. Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.
Plüß M; Mese K; Kowallick JT; Schuster A; Tampe D; Tampe B
Front Immunol; 2021; 12():784145. PubMed ID: 35116025
[TBL] [Abstract][Full Text] [Related]
49. High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.
Pietersma FL; van Dorp S; Jacobi R; Ran L; Nanlohy NM; Schuurman R; Minnema MC; Meijer E; van Baarle D
Clin Infect Dis; 2010 Mar; 50(5):717-25. PubMed ID: 20121571
[TBL] [Abstract][Full Text] [Related]
50. High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis.
Pischke S; Gösling J; Engelmann I; Schlue J; Wölk B; Jäckel E; Meyer-Heithuis C; Lehmann U; Strassburg CP; Barg-Hock H; Becker T; Manns MP; Schulz T; Wedemeyer H; Heim A
J Hepatol; 2012 May; 56(5):1063-1069. PubMed ID: 22245897
[TBL] [Abstract][Full Text] [Related]
51. Early cytomegalovirus reactivation leaves a specific and dynamic imprint on the reconstituting T cell compartment long-term after hematopoietic stem cell transplantation.
Lugthart G; van Ostaijen-Ten Dam MM; Jol-van der Zijde CM; van Holten TC; Kester MG; Heemskerk MH; Bredius RG; van Tol MJ; Lankester AC
Biol Blood Marrow Transplant; 2014 May; 20(5):655-61. PubMed ID: 24462981
[TBL] [Abstract][Full Text] [Related]
52. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.
Lebon D; Dujardin A; Caulier A; Joris M; Charbonnier A; Gruson B; Quint M; Castelain S; François C; Lacassagne MN; Guillaume N; Marolleau JP; Morel P
Leuk Res; 2023 Feb; 125():107005. PubMed ID: 36580876
[TBL] [Abstract][Full Text] [Related]
53. Impact of cytomegalovirus reactivation on clinical outcomes in immunocompetent critically ill patients: protocol for a systematic review and meta-analysis.
Lachance P; Chen J; Featherstone R; Sligl W
Syst Rev; 2016 Jul; 5(1):127. PubMed ID: 27465807
[TBL] [Abstract][Full Text] [Related]
54. Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study.
Kim YS; Kim YH; Kim JS; Jeong SY; Park SJ; Cheon JH; Ye BD; Jung SA; Park YS; Choi CH; Kim KO; Jang BI; Han DS; Yang SK; Kim WH
Gut Liver; 2014 Nov; 8(6):643-7. PubMed ID: 25368753
[TBL] [Abstract][Full Text] [Related]
55. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
[TBL] [Abstract][Full Text] [Related]
56. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection.
Aalto SM; Linnavuori K; Peltola H; Vuori E; Weissbrich B; Schubert J; Hedman L; Hedman K
J Med Virol; 1998 Nov; 56(3):186-91. PubMed ID: 9783683
[TBL] [Abstract][Full Text] [Related]
57. Isolation of Epstein-Barr virus-deoxyribonucleic acid in the lower respiratory tract for distinguishing critically ill patients from those with influenza-associated pneumonia: A pilot study.
Bai Y; Guo Y; Chen X; Yang C; Gu L
Clin Respir J; 2023 Dec; 17(12):1246-1253. PubMed ID: 37823412
[TBL] [Abstract][Full Text] [Related]
58. Viral reactivations and co-infections in COVID-19 patients: a systematic review.
Kim JYH; Ragusa M; Tortosa F; Torres A; Gresh L; Méndez-Rico JA; Alvarez-Moreno CA; Lisboa TC; Valderrama-Beltrán SL; Aldighieri S; Reveiz L
BMC Infect Dis; 2023 Apr; 23(1):259. PubMed ID: 37101275
[TBL] [Abstract][Full Text] [Related]
59. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
60. Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice.
Cook CH; Zhang Y; Sedmak DD; Martin LC; Jewell S; Ferguson RM
Crit Care Med; 2006 Mar; 34(3):842-9. PubMed ID: 16521279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
